On the basis of type, the prescription drugs market is segmented into branded and generic. The branded drugs segment dominated the market with the largest revenue share of 62.5% in 2024, attributed to patent exclusivity, strong marketing strategies, and clinical preference in specialty therapeutics. The growing chronic diseases among the elderly population contribute to the segment’s growth. The growing awareness about chronic diseases like diabetes, cancer, and cardiovascular disease is also fueling the need for prescribed medicines. Governments worldwide have implemented favorable reimbursement policies for prescribed medication, bolstering the segment growth. The growth of the prescription segment has a significant impact on the overall U.S. pharmacy industry.
This move is expected to accelerate the adoption of modernized pharmacy operations and drive the growth of the hospital and corporation segment. Additionally, pharmacies offer medication therapy management services to 73% of customers, compression socks and hosiery to 72%, smoking cessation aids to 61%, compounding to 52%, and ostomy supplies to 30%. These services help pharmacies to provide better patient care, which can lead to increased customer loyalty and medication sales. The other segment contains critical and life-saving drugs such as oncology, anti-diabetic and cardiovascular drugs and has been instrumental in the dominance of this segment in the global market.
Competition Among Small Molecule Drugs And Biological
Without this investment in education and communication, even the most promising and cost-effective products may fail to achieve their full market potential. The convergence of these innovations—complex products, advanced manufacturing, and digital commercial models—is creating a profound divergence within the generic drug industry. Companies that possess the capital, expertise, and strategic foresight to invest in these new capabilities will be able to create a sustainable competitive advantage based on value, quality, and efficiency.
Accelerating Geriatric Patients With Chronic Diseases Is Driving The Asia Pacific
One of the critical elements driving the global market growth is the increasing launches of the generic equivalents of several key drugs in strong markets such as the U.S. The increasing adoption of these generic equivalents is especially due to the fact that these generics are often as efficient as their original counterparts and can often be adopted by patients at a fraction of the costs. Patients without access to expensive prescription products due to financial hurdles can often adopt these drugs and experience better clinical outcomes. FDA announced that they had given 1,171 generic drug approvals, of which 935 were full approvals and 236 were tentative approvals. The U.S. FDA particularly approved these generic equivalents to improve drug competition and to also encourage the increasing adoption of these low-cost drug equivalents.
The expansion of pharmacy chains, growing online pharmacy adoption, and rising health awareness contribute to market growth. Retail pharmacies offer accessible healthcare services, including vaccinations and chronic disease management support. In addition, the demand for self-medication, cost-effective treatment options, and the availability of prescription fulfillment services further enhance the segment’s growth prospects.
How Many Segments Are Included In The Drug Market, And What Are They?
- The market is driven by rising prevalence of chronic diseases, new drug launches, and increasing healthcare expenditure.
- The growth of the prescription segment has a significant impact on the overall U.S. pharmacy industry.
- Furthermore, regulatory backing that embraces the unique characteristics of biologics and biosimilars, establishing specific approval processes and guidelines, is significantly contributing to the segment’s growth.
- Frequent users may account for a large share of the drug-selling workforce and sellers may account for a large share of total consumption; selling is a highly opportunistic activity, so that most dealers do it only on an occasional basis (e.g., Reuter et al., 1990).
- Lastly, favorable regulatory pathways & expedited approvals for breakthrough cancer therapies have further propelled the growth of this segment, solidifying its dominance in the U.S.
- For example, Rhodes and colleagues (2002) assume very elastic cocaine supply on the grounds that the agricultural production technology is simple and inexpensive.
When examining small molecule drugs, 57 percent had at least 2manufacturers, whereas only 19 percent of biological products had at least 2manufacturers. However, once we narrowed the market to only specialty drugsand the highest priced drugs, then competition in both markets erodedsubstantially. Among specialty drugs, 63 percent of small molecule drugs and87 percent of biological products had only a single manufacturer.
Biologics is revolutionizing chronic disease treatments, and biosimilars are enabling cost-effective therapies. The rising prevalence of chronic disease, increasing healthcare costs, and expiring patents on the blockbuster biologic have led to a surge in the use of biologics and biosimilars. As a result, pharmaceutical companies are increasingly focusing on the development of biologics and biosimilars, which provide new treatment options. In the US market, the growing geriatric population with chronic conditions like diabetes, heart disease, and cancer is fuelling the demand for medications, which ultimately enhances the expansion of the market. Furthermore, supportive govement programs such as Medicare and Medicaid are majorly influencing healthcare expenses, contributing to a rise in demand for drugs.
- These generics are affordable alteatives to brand-name drugs and have significantly contributed to reducing healthcare expenses.
- With 30 street dealers, this would total about two sales per dealer per day, assuming that individuals sell only about half the days of the year.
- Additionally, pharmacies offer medication therapy management services to 73% of customers, compression socks and hosiery to 72%, smoking cessation aids to 61%, compounding to 52%, and ostomy supplies to 30%.
- Drug enforcement is about market regulation, yet the federal government makes little effort to collect systematic market data.
- The National Pharmaceutical Policy helps cut costs and reduce reliance on Chinese API imports.
The Human Element: Patient And Physician Perspectives
Factors such as the expansion of retail and online pharmacies, regulatory approvals for prescription-to-OTC switches, and marketing initiatives contributed to market growth. The demand for OTC products addressing common conditions such as colds, allergies, and pain management further supported the segment. In addition, cost-effectiveness and convenience, along with growing awareness through digital platforms, enhanced consumer adoption, positioning the OTC segment as a key growth driver in the market. The generic segment is expected to register the fastest growth rate over the projected period, driven by a high number of patent expiries in 2024, increasing demand for affordable medications, and rising healthcare expenditure. Supportive regulatory frameworks and cost-containment measures by governments and healthcare providers are further encouraging the adoption of generics. The segment’s growth is also bolstered by improved manufacturing capabilities, enhanced distribution networks, and growing awareness among patients and healthcare professionals regarding the effectiveness of generic alternatives.
See Markets More Clearly Opportunities More Often
Market players adopt this strategy to expand the outreach of their service in the market and increase the availability of their service in diverse geographical areas. In addition, hospital and corporation chains are also providing quality care while implementing innovative technologies such as automated medication dispensing systems, electronic health records, and digital pharmacies. These technologies are expected to further drive the growth of the segment by improving efficiency and accuracy while reducing costs. According to a report by the Assistant Secretary for Planning and Evaluation (ASPE), there has been a change in the location where Americans receive their drugs. Between 2016 and 2021, there has been a 95% increase in the number of Americans receiving their drugs from home health care.
Complex Generics: The New Competitive Battleground
Market players compete based on factors such as product quality, pricing, supply chain efficiency, regulatory compliance, and market reach. The entry barriers for generic drug manufacturers are relatively lower compared to the branded drug market, which contributes to a highly competitive environment. The generic drugs market in the Asia Pacific region is experiencing significant growth and presents lucrative opportunities for pharmaceutical companies. With a significant 20% share in the global supply, India manufactures around 60,000 different generic brands across 60 therapeutic categories. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) was launched in India to ensure the availability of quality generic medicines at affordable prices, especially for disadvantaged populations.
The hospital pharmacy segment dominated the peptide drug conjugates market with a revenue share of 53.53% in 2024 due to increasing hospital admissions, rising demand for specialized treatments, and access to a wide range of prescription medications. Hospitals serve as primary points for acute care, chronic disease management, and surgical procedures, driving medication demand through in-house pharmacies. The availability of advanced therapies, including biologics and injectable drugs, further supports this dominance.
Circumvent The Tariff Challenges With An Agile Supply Chain Consulting
By product type, the over-the-counter (OTC) drugs segment is expected to be the fastest CAGR growing in the upcoming years. Nowadays, consumers are widely adopting OTC drugs to resolve insignificant ailments and track their complete well-being, because of their convenience and reasonable compared to prescription drugs. Also, rising emphasis on proactive health management is resulting in a greater demand for OTC products, which is coupled with self-care and preventive measures. The worldwide drugs market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034.
Prescription Drugs Market Trends
The technological disruption extends beyond the lab and factory floor to the commercial landscape itself. The rise of digital platforms is changing how generic drugs are distributed and accessed, creating new pressures and opportunities. Maintaining impeccable quality is not just a regulatory requirement but a matter of public trust.
List Of Key Companies In US Prescription Drugs Market
The Germany prescription drugs market is expected to expand at a considerable CAGR during the forecast period, driven by its advanced healthcare infrastructure and strong pharmaceutical manufacturing base. Germany’s emphasis on innovation, biosimilar adoption, and health insurance reimbursement policies has fostered a competitive and high-value prescription drugs environment. Furthermore, increased government focus on improving healthcare efficiency and sustainability continues to support the growth of prescription drug utilization across hospitals and specialty care settings.
Such economic models as efficiency wage theory seek to explain why wages persist above the market-clearing level (Akerlof and Yellen, 1986). That comparison shows that the magnitudes of the effects of the same supply-side intervention depend on the steepness of the demand curve for drugs. The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data. Spotlight on Maryland asked BPD on Thursday morning if the agency could confirm the number of arrests of participants in the city’s drug markets. Two BPD officers, who requested anonymity because they are not authorized to speak to the media, told Spotlight on Maryland on Saturday that they are among several others citywide who are tired of open-air drug markets operating unchecked in Baltimore.
